[vc_row][vc_column][vc_column_text] The global therapeutic IPO market has failed to maintain the upward momentum established throughout a busy Q2 2017, with just over $1B raised by 13 […]
[vc_row][vc_column][vc_column_text] Gilead Sciences has ended its M&A moratorium with an $11.9B all-cash acquisition of CAR-T Cell Therapy pioneers Kite Pharma. Kite’s leading drug Axi-Cel is expected […]